Should You Add Teleflex Stock to Your Portfolio Now?

Teleflex’s TFX interventional arm is positioned for continued growth, according to Zacks Investment Research, driven by demand for central access and hemostatic products and by new introductions such as EZPLAZ. The company’s Vascular business posted revenue growth in Q2 2026, rising 9% on a reported basis and 8% on a pro forma, adjusted constant-currency basis. Management said it worked through a lidocaine recall and related back orders during the quarter, with distributor inventory expected to normalize in the second half. In late July 2026, the FDA approved EZPLAZ Freeze Dried Plasma, described as the first freeze-dried plasma licensed by the agency. Zacks also highlighted the BIOTRONIK Vascular Intervention acquisition expanding the interventional platform, along with clinical development progress for Freesolve.